Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.63 on revenue of $519.4M. Analysts polled by Investing.com anticipated EPS of $0.2024 on revenue of $511.08M.
Biomarin Pharma shares are down 9.1% from the beginning of the year and are trading at $82.00 , down-from-52-week-high.They are outperforming the Nasdaq which is down 20.17% from the start of the year.
Biomarin Pharma shares gained 2.10% in after-hours trade the report.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by UnitedHealth on April 14, who reported EPS of $5.49 on revenue of $80.15B, compared to forecasts EPS of $5.36 on revenue of $78.73B.
J&J had beat expectations on April 19 with first quarter EPS of $2.67 on revenue of $23.43B, compared to forecast for EPS of $2.59 on revenue of $23.62B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar